Two Sigma Investments LP acquired a new stake in AstraZeneca plc (NYSE:AZN) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 886,691 shares of the company’s stock, valued at approximately $30,768,000.
Several other hedge funds have also recently added to or reduced their stakes in AZN. Pinnacle Wealth Planning Services Inc. bought a new position in shares of AstraZeneca in the fourth quarter valued at approximately $101,000. Valeo Financial Advisors LLC bought a new position in shares of AstraZeneca in the third quarter valued at approximately $133,000. Delpha Capital Management LLC bought a new position in shares of AstraZeneca in the fourth quarter valued at approximately $152,000. Calton & Associates Inc. bought a new position in shares of AstraZeneca in the fourth quarter valued at approximately $181,000. Finally, Wealthcare Advisory Partners LLC bought a new position in shares of AstraZeneca in the third quarter valued at approximately $184,000. Institutional investors own 15.14% of the company’s stock.
A number of research firms have recently commented on AZN. BMO Capital Markets set a $40.00 price objective on shares of AstraZeneca and gave the company a “buy” rating in a research report on Thursday, March 22nd. ValuEngine lowered shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 7th. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, March 20th. Jefferies Group upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating and raised their price objective for the company from $28.43 to $36.70 in a research report on Monday, March 19th. Finally, Sanford C. Bernstein raised their target price on shares of AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Three research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $38.12.
Shares of AZN opened at $35.42 on Friday. The company has a market capitalization of $89,208.60, a P/E ratio of 8.28, a P/E/G ratio of 1.83 and a beta of 0.62. AstraZeneca plc has a 1-year low of $28.43 and a 1-year high of $36.70. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.93.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings results on Friday, February 2nd. The company reported $1.30 EPS for the quarter, topping the consensus estimate of $0.44 by $0.86. The firm had revenue of $5.78 billion for the quarter, compared to the consensus estimate of $5.49 billion. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The business’s revenue was up 3.4% compared to the same quarter last year. During the same period last year, the firm posted $1.21 earnings per share. analysts anticipate that AstraZeneca plc will post 1.7 EPS for the current fiscal year.
The firm also recently declared a semiannual dividend, which was paid on Monday, March 19th. Shareholders of record on Friday, February 16th were paid a dividend of $0.95 per share. This represents a dividend yield of 5.62%. The ex-dividend date was Thursday, February 15th. AstraZeneca’s dividend payout ratio (DPR) is presently 32.01%.
ILLEGAL ACTIVITY WARNING: This article was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/two-sigma-investments-lp-takes-position-in-astrazeneca-plc-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.